Organon acquires Karolinska Development’s portfolio company Forendo Pharma at a total purchase price of USD 945 million provided fulfilment of all milestones
Go back to Organon acquires Karolinska Development’s portfolio company Forendo Pharma at a total purchase price of USD 945 million provided fulfilment of all milestones| Merck & Co. (NYSE: MRK) | Delayed: 129.56 +4.19 (3.34%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $125.37 | 52 Week High | $65.46 | |||
| Open | $126.18 | 52 Week Low | $47.97 | |||
| Day High | $129.61 | P/E | 88.14 | |||
| Day Low | $125.99 | EPS | $1.47 | |||
| Volume | 7,833,992 | |||||
| (NYSE: OGN) | Delayed: 13.55 +0.02 (0.15%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $13.53 | 52 Week High | $8.00 | |||
| Open | $13.57 | 52 Week Low | $8.00 | |||
| Day High | $13.59 | P/E | N/A | |||
| Day Low | $13.53 | EPS | $0.00 | |||
| Volume | 1,508,071 | |||||
